BIIB vs. TMO: Biogen vs. Thermo Fisher Scientific Stock Comparison

November 11, 2026

How do Biogen (BIIB) and Thermo Fisher Scientific (TMO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Biogen (BIIB) and Thermo Fisher Scientific (TMO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIIB is classified in Biotechnology while TMO is classified in Life Sciences Tools & Services.

Company profile comparison for Biogen (BIIB) and Thermo Fisher Scientific (TMO)
Profile Item	BIIB	TMO
Name	Biogen Inc.	Thermo Fisher Scientific Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	36.71 billion USD	257.42 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	September 17, 1991	March 17, 1980
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

BIIB

TMO

GSPC

Biogen (BIIB) vs. Thermo Fisher Scientific (TMO), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Biogen (BIIB) and Thermo Fisher Scientific (TMO). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Biogen (BIIB) and Thermo Fisher Scientific (TMO). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Biogen (BIIB) and Thermo Fisher Scientific (TMO)
Metric	BIIB	TMO
Total Return (1Y)	65.44%	24.62%
Total Return (3Y, Annualized)	4.62%	17.34%
Total Return (5Y, Annualized)	-0.96%	3.11%

Risk Profile

Drawdown History

BIIB

TMO

GSPC

Biogen (BIIB) vs. Thermo Fisher Scientific (TMO), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Biogen (BIIB) and Thermo Fisher Scientific (TMO). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Biogen (BIIB) and Thermo Fisher Scientific (TMO)
Metric	BIIB	TMO
Volatility (1Y, Annualized)	34.58%	29.96%
Beta (5Y)	0.08	0.83
Max Drawdown (5Y)	-64.35%	-40.95%
Avg. Volume (3M)	1.05M	2.10M

Risk-Adjusted Performance

Risk-Return Positioning

BIIB and TMO are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Biogen (BIIB) and Thermo Fisher Scientific (TMO)
Metric	BIIB	TMO
Sharpe Ratio (1Y)	1.77	0.68
Sortino Ratio (1Y)	2.77	1.02

Profitability

ROE (TTM)

Thermo Fisher Scientific (TMO) at 13.38% sits in the top ROE quartile, while Biogen (BIIB) at 1.87% is closer to the peer norm — stronger capital efficiency for TMO.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.87%

Max: 109.18%
Q3: 6.23%
BIIB: 1.87%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.38%

Max: 109.18%
TMO: 13.38%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Biogen (BIIB) vs. Thermo Fisher Scientific (TMO): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Thermo Fisher Scientific (TMO) at 14.94% retains a top-quartile share of revenue as profit, ahead of Biogen (BIIB) at 3.38%, which keeps about the industry-typical share.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.38%

Max: 18.05%
Q3: 4.78%
BIIB: 3.38%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.94%

Max: 18.05%
TMO: 14.94%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Biogen (BIIB) vs. Thermo Fisher Scientific (TMO): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Biogen (BIIB) at 24.12% and Thermo Fisher Scientific (TMO) at 20.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.12%

Max: 83.12%
BIIB: 24.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.19%

Max: 83.12%
TMO: 20.19%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Biogen (BIIB) vs. Thermo Fisher Scientific (TMO): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Biogen (BIIB) and Thermo Fisher Scientific (TMO)
Metric	BIIB	TMO
ROE (TTM)	1.87%	13.38%
ROA (TTM)	4.94%	5.19%
Net Margin (TTM)	3.38%	14.94%
Operating Margin (TTM)	24.12%	20.19%
Gross Margin (TTM)	75.77%	41.26%

Growth

Revenue Growth

Both Biogen (BIIB) at 2.22% and Thermo Fisher Scientific (TMO) at 3.91% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Biogen (BIIB) vs. Thermo Fisher Scientific (TMO): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Biogen (BIIB) at -21.38% and Thermo Fisher Scientific (TMO) at 7.32% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Biogen (BIIB) vs. Thermo Fisher Scientific (TMO): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Biogen (BIIB) and Thermo Fisher Scientific (TMO)
Metric	BIIB	TMO
Revenue Growth (YoY)	2.22%	3.91%
Revenue Growth (3Y CAGR)	-0.94%	-0.27%
EPS Growth (YoY)	-21.38%	7.32%
EPS Growth (3Y CAGR)	-25.04%	0.21%

Financial Strength

Current Ratio (MRQ)

Both Biogen (BIIB) at 1.95 and Thermo Fisher Scientific (TMO) at 1.81 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.95

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
BIIB: 1.95
Min: 0.10

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.81

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
TMO: 1.81
Min: 0.10

Biogen (BIIB) vs. Thermo Fisher Scientific (TMO): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Biogen (BIIB) at 0.41 carries an industry-typical debt-to-equity mix, while Thermo Fisher Scientific (TMO) at 0.75 uses more debt funding than most peers.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41

Max: 1.42
Q3: 0.65
BIIB: 0.41
Median: 0.15
Q1: 0.02
Min: 0.00

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.75

Max: 1.42
TMO: 0.75
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Biogen (BIIB) vs. Thermo Fisher Scientific (TMO): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Biogen (BIIB) and Thermo Fisher Scientific (TMO)
Metric	BIIB	TMO
Current Ratio (MRQ)	1.95	1.81
Debt / Equity (MRQ)	0.41	0.75
Net Debt / EBITDA	1.97	2.91

Dividends

Dividend Yield (TTM)

Biogen (BIIB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a yield of 0.27%, ranking against industry peers normally.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.27%

TMO: 0.27%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Biogen (BIIB) vs. Thermo Fisher Scientific (TMO): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Biogen (BIIB) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a payout of 9.70%, ranking against industry peers normally.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.70%

TMO: 9.70%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Biogen (BIIB) vs. Thermo Fisher Scientific (TMO): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Biogen (BIIB) and Thermo Fisher Scientific (TMO)
Metric	BIIB	TMO
Dividend Yield (TTM)	0.00%	0.27%
Dividend Payout Ratio (TTM)	0.00%	9.70%

Valuation

P/E Ratio (TTM)

Thermo Fisher Scientific (TMO) at 36.64 is near its industry’s usual P/E ratio, while Biogen (BIIB) at 107.51 sits above its peer range — an unusually expensive price for BIIB’s trailing earnings.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

107.51

BIIB: 107.51
Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.64

Max: 85.34
Q3: 43.46
TMO: 36.64
Median: 26.69
Q1: 13.30
Min: 0.07

Biogen (BIIB) vs. Thermo Fisher Scientific (TMO): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Biogen (BIIB) at 3.57 and Thermo Fisher Scientific (TMO) at 5.44 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.57

Max: 58.18
Q3: 25.77
Median: 7.30
BIIB: 3.57
Q1: 3.01
Min: 0.01

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.44

Max: 58.18
Q3: 25.77
Median: 7.30
TMO: 5.44
Q1: 3.01
Min: 0.01

Biogen (BIIB) vs. Thermo Fisher Scientific (TMO): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Biogen (BIIB) at 1.94 and Thermo Fisher Scientific (TMO) at 4.70 are valued close to their industries’ norm against book — neither stands out from peers.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94

Max: 13.53
Q3: 6.54
Median: 3.25
BIIB: 1.94
Q1: 1.69
Min: -5.59

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70

Max: 13.53
Q3: 6.54
TMO: 4.70
Median: 3.25
Q1: 1.69
Min: -5.59

Biogen (BIIB) vs. Thermo Fisher Scientific (TMO): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Biogen (BIIB) and Thermo Fisher Scientific (TMO)
Metric	BIIB	TMO
P/E Ratio (TTM)	107.51	36.64
P/S Ratio (TTM)	3.57	5.44
P/B Ratio (MRQ)	1.94	4.70
Free Cash Flow Yield (TTM)	2.20%	2.50%